Comparative Pharmacology
Head-to-head clinical analysis: CEFAZOLIN AND DEXTROSE versus TAZIDIME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFAZOLIN AND DEXTROSE versus TAZIDIME.
CEFAZOLIN AND DEXTROSE vs TAZIDIME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bactericidal agent inhibiting bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis. Dextrose provides osmotic diuresis and energy source.
Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and disrupting peptidoglycan cross-linking.
1-2 g IV/IM every 8 hours; maximum 12 g/day.
1 to 2 g IV/IM every 8 hours; maximum 6 g/day.
None Documented
None Documented
1.8 hours (prolonged to 20-40 hours in severe renal impairment, CrCl <10 mL/min)
Clinical Note
moderateCeftazidime + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Ceftazidime."
Clinical Note
moderateCeftazidime + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ceftazidime."
Clinical Note
moderateWarfarin + Ceftazidime
"Warfarin may increase the anticoagulant activities of Ceftazidime."
Clinical Note
moderatePhenprocoumon + Ceftazidime
1.9 hours (range 1.5-2.8 hours); prolonged in renal impairment (up to 20 hours in ESRD).
Renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal (<5%)
Primarily renal (80-90% unchanged via glomerular filtration), biliary/fecal <5%.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"Phenprocoumon may increase the anticoagulant activities of Ceftazidime."